Results 221 to 230 of about 68,611 (312)

A Surface‐engineered Microfluidic Device for Antibody‐Mediated Negative Selection of High‐Quality Sperm for Assisted Reproduction

open access: yesAdvanced Functional Materials, Volume 36, Issue 47, 11 June 2026.
This study reports a microfluidic device with a functionalized surface utilizing a polyoxazoline coating and covalently immobilized gold nanoparticles and anti‐phosphatidylserine antibody. The device efficiently eliminates pre‐apoptotic and apoptotic spermatozoa and yields sperm with substantially improved quality and low DNA damage, offering a simple ...
Soraya Rasi Ghaemi   +5 more
wiley   +1 more source

Enhanced Human Antigen‐Specific B Cell Responses Using In Vitro 3D Tonsil Cultures Containing Stromal Cells

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 22, 12 June 2026.
We developed a fully human 3D tonsil cell culture system incorporating supportive stromal cells that better sustains and activates immune cells than conventional methods. The model generates stronger, more targeted antibody responses to viral antigens and vaccines, providing a physiologically relevant and entirely human platform for studying immune ...
Maaike V. J. Braham   +11 more
wiley   +1 more source

A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals

open access: yesAdvanced Materials, Volume 38, Issue 33, 12 June 2026.
A cryoprotectant‐compatible nanoporous platform enables ambient‐stable and scalable delivery of gene editing therapeutics. By combining hierarchical pore architecture with optimized lyophilization chemistry, the system preserves Cas9‐RNP activity post‐freeze‐drying.
Sian Lee   +8 more
wiley   +1 more source

Cryopreservation preserves the morpho-structural and mechanical integrity of human decellularized tracheas and supports a reduced immunogenic profile. [PDF]

open access: yesFront Bioeng Biotechnol
Stocco E   +12 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy